Controlling hypertension immediately post stroke: a cost utility analysis of a pilot randomised controlled trial by Wilson, Edward CF et al.
RESEARCH Open Access
Controlling hypertension immediately post stroke:
a cost utility analysis of a pilot randomised
controlled trial
Edward CF Wilson
1*, Gary A Ford
2, Tom Robinson
3, Amit Mistri
3, Carol Jagger
4, John F Potter
1
Abstract
Background: Elevated blood pressure (BP) levels are common following acute stroke. However, there is
considerable uncertainty if and when antihypertensive therapy should be initiated.
Method: Economic evaluation alongside a double-blind randomised placebo-controlled trial (National Research
Register Trial Number N0484128008) of 112 hypertensive patients receiving an antihypertensive regimen (labetalol
or lisinopril) within 36 hours post stroke versus 59 receiving placebo. Outcomes were incremental cost per
incremental: QALY, survivor, and patient free from death or severe disability (modified Rankin scale score < 4) at
three months and 14 days post stroke.
Results: Actively treated patients on average had superior outcomes and lower costs than controls at three
months. From the perspective of the acute hospital setting, there was a 96.5% probability that the incremental cost
per QALY gained at three months is below £30,000, although the probability may be overstated due to data
limitations.
Conclusion: Antihypertensive therapy when indicated immediately post stroke may be cost-effective compared
with placebo from the acute hospital perspective. Further research is required to confirm both efficacy and cost-
effectiveness and establish whether benefits are maintained over a longer time horizon.
Background
Approximately 52,000 patients experience first stroke
[1], and 135,000 experience first or recurrent stroke in
England and Wales each year [2]. It is the third biggest
cause of death and the most important single cause of
severe adult disability [3]. The societal cost of stroke to
England and Wales is estimated at £7bn, of which 40%
are direct care costs, 35% informal care, and the remain-
ing 25% indirect costs (lost productivity) [4].
Elevated blood pressure (BP) levels are common fol-
lowing onset of acute stroke, and observational data sug-
gest that both high and low BP levels are associated with
poor short and long term prognosis [5-16]. The acute
management of post-stroke BP changes is a matter of
some debate, with considerable differences of opinion
on when to initiate antihypertensive therapy [17]. A
Cochrane review of BP manipulation following stroke
concluded that there was insufficient evidence to evalu-
ate the effect of changes on patient outcomes [18].
In view of the uncertainty surrounding appropriate
response to BP control in the acute post-stroke phase,
the Control of Hypertension and Hypotension Immedi-
ately Post Stroke (CHHIPS) trial (National Research
Register Trial Number N0484128008) aimed to establish
the safety, efficacy and cost-effectiveness of reducing BP
with labetalol or lisinopril in hypertensive patients with
acute cerebral infarction or haemorrhage, and of raising
BP with phenylephrine in hypotensive patients with
ischaemic stroke.
As resources are finite, decision making requires con-
sideration not only of the benefits to a patient of a
health care intervention, but its impact on other patients
consuming other diverse health care services: commit-
ting resources to one intervention means they cannot be
e m p l o y e d ,o rm u s tb ew i t h d r a w nf r o m ,e l s e w h e r e .A n
economic evaluation considers the cost and conse-
quences of two or more treatment strategies, and shows
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strategy in place of old [19]. The change in cost divided
by the change in outcome (the incremental cost-effec-
tiveness ratio or ICER) is then compared with a maxi-
mum ‘threshold’. This threshold can be interpreted as
the cost-effectiveness of the least efficient service cur-
rently provided by the health service (although alterna-
tive interpretations of the threshold exist). If the ICER is
below this threshold, adopting the new treatment (and
by implication ceasing the least efficient service) will
improve the net health gain to the population. Conver-
sely, adopting a treatment whose ICER is above the
threshold will lead to a net reduction in health gain to
the population. An outcome measure commonly used to
make these comparisons is the Quality Adjusted Life
Year (QALY), and the threshold in the UK is considered
to be in the region of £20,000 - £30,000 per QALY
gained [20].
We report a cost-utility and cost-effectiveness analysis
of therapeutically reducing blood pressure compared
with no therapeutic reduction in blood pressure in hos-
pitalised hypertensive patients with acute cerebral
infarction or haemorrhage.
Methods
Full details of the methods and outcome measures in
the study are reported elsewhere [21-23]. The study was
designed to include both pressor and depressor trial
arms. Due to low recruitment, the pressor arm of the
trial was terminated early. We therefore report costs
and outcomes relating to the depressor arm only.
Briefly, 179 patients aged 18+ years with a clinical
diagnosis of stroke (cerebral infarct or haemorrhage)
with onset ≤ 36 hours and systolic blood pressure (SBP)
≥ 160 mmHg were enrolled into this randomised dou-
ble-blind placebo-controlled trial. Exclusion criteria
included on antihypertensive therapy at time of stroke
onset (amended during study to allow inclusion of dys-
phagic patients on antihypertensive therapy) or an
urgent indication for BP lowering, significant co-mor-
bidity, or a life expectancy ≤ six months due to non-
stroke causes prior to stroke onset.
Following baseline assessment (SBP levels, time of stroke
onset, swallowing status, functional assessments including
modified Rankin scale (mRS) and National Institute of
Health Stroke Scale (NIHSS)), patients were randomised
on a 2:1 ratio between active treatment and placebo.
Active treatment comprised stepped doses of oral (for
non-dysphagic) or intravenous/sublingual routes of labeta-
lol or lisinopril respectively with a target SBP of 145-155
mmHg or a SBP fall of ≥ 15 mmHg. Additional doses
were administered at 4 and 8 hours post randomisation if
targets were not met. Controls were administered match-
ing placebo, and the regimen continued for 14 days post
randomisation. Dysphagic patients underwent similar
titrated dosing but with sublingual lisinopril 5 mg, intrave-
nous labetalol 50 mg or matching placebo for 72 hours,
then oral therapy (if possible), or via nasogastric tube until
day 14. Subsequently all patients followed local guidelines
as regards antihypertensive therapy (usually an ACE inhi-
bitor and/or diuretic). At day 14 and 3 months post rando-
misation, mRS was completed.
Baseline and two week assessments were performed by
research staff at the local centres. Three month follow-
up was by telephone administered from the trial coordi-
nating centre. Where participants were not able to recall
date of discharge at the three month follow-up, the local
research staff were contacted to obtain the date from
hospital records.
The primary outcomes were incremental cost per
incremental survivor and incremental cost per incre-
mental QALY gained at 3 months post randomisation
with active treatment versus placebo. Secondary analyses
comprised incremental cost per incremental: patient
with death or severe disability (defined as mRS score <
4) at 14 days and 3 months, and survivor and QALY
gained at 14 days.
Utilities were mapped to mRS scores estimated from a
study of 459 individuals eliciting utilities from mRS
scores using the time trade-off (TTO) approach [24].
The analysis was conducted from the perspective of
the acute hospital. Hence resource use data comprised
patient length of stay and study drug consumption. The
price year of the study was 2006. Length of stay (LoS)
was calculated as the difference between date of death
or discharge and date of randomisation. The bulk of
hospitalisation costs tend to be skewed towards the first
few days of admission and the National Schedule of
Reference Costs 2006 [25] estimates the mean cost of a
stroke admission at £2642, with a mean length of stay of
11 days, and a daily cost of excess bed-days of £176. We
therefore approximated the cost of an admission as:
Cost of admission   2642 LoS 11 176    *
Per patient cost of study drugs was estimated as num-
ber of tablets or vials multiplied by unit cost (lisinopril @
£1.34/28 5 mg tabs, labetalol @ £3.79/56 50 mg tabs and
£2.12/20 ml ampoule[26]). Placebo was costed at zero.
We present results as quantities of resource use and
total cost, and outcomes by treatment group (active
treatment vs placebo). The incremental cost-effective-
ness ratio (ICER) was calculated as
ICER   C2   C1 E2   E1 –/–    
Uncertainty in the point estimate ICER was investi-
gated by means of a non-parametric bootstrap with
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intervals around incremental cost and outcomes, and to
generate the cost-effectiveness acceptability curve
(CEAC). The CEAC shows the treatment (active or pla-
cebo) with the highest probability of being cost-effective
at varying thresholds of willingness to pay for a unit of
outcome, and is a means of expressing uncertainty
around point estimates [27].
Results are presented as cost of each arm and incre-
ment, outcome from each arm and increment, and
incremental cost-effectiveness (Table 1). The figures
reported in Table 1 are based on complete case analysis
(observations for which both cost and outcome data
were available). Tables 2 and 3 report disaggregated
resource use and cost, and outcomes using all observa-
tions for which cost or outcomes data were available
(see Figure 1 for details).
Results
Of 179 patients randomised to the trial, eight were with-
drawn post randomisation (see Potter et al. [23] for
details of post-randomisation exclusions). Resource use
data at 14 days and three months were available on 171
(Active = 112, Placebo = 59) and 162 (Active = 105, Pla-
cebo = 57) patients respectively. Utility data based on
mRS score at baseline and 14 days were available on all
171 patients. However at three months, mRS and hence
mRS-based utilities and QALYs gained were available
on 32 (Active = 18, Placebo = 14) patients. Survival sta-
tus up to three months was recorded in all 171 patients.
Therefore full cost and outcomes data were available on
171 (Active = 112, Placebo = 59) patients at 14 days. At
three months cost and survival data were available on
162 (Active = 105, Placebo = 57) patients, and cost and
death/disability and cost and QALY data on 31 (Active =
17, Placebo = 14) patients (Figure 1).
There were no substantial differences in baseline charac-
teristics between active and placebo treatment groups [23].
Cost effectiveness
There were no significant differences in cost or out-
comes at 14 days (Table 1, analyses 1-3). At three
months, active treatment per patient was (non-signifi-
cantly) decreased by between £1000 and £5511 (Ana-
lyses 4-6 Table 1), with a gain of 0.044 QALYs (95% CI
0.000, 0.086; Analysis 6 Table 1). Survival at three
months favoured active treatment (+11.5%, 95%CI:
+0.1%, +23.2%; Analysis 4 Table 1), as did proportion
free from death or severe disability (+34.0%, 95%CI:
+8.0%, +58.8%; Analysis 5 Table 1). The difference in
Table 1 Cost utility and cost effectiveness analyses at 14 days and 3 months (Complete case analysis)
n £ Outcome
A P A P Increment (95% CI) A P Increment (95% CI) ICER P(ICER ≤ £30k)**
1. 14d survival* 112 59 2553 2525 28 (-228, 269) § 0.955 0.898 0.057 (-0.028, 0.144) £490
2. 14d D&D† 112 59 2553 2525 28 (-215, 278) § 0.393 0.407 -0.014 (-0.169, 0.149) [P dominant]
3. 14d CUA‡ 112 59 2553 2525 28 (-226, 268) § 0.028 0.027 0 (-0.001, 0.002) £76,162 45.9%
4. 3 m survival* 105 57 8234 9233 -1000 (-3760, 1588) 0.905 0.789 0.115 (0.001, 0.232) [A dominant]
5. 3 m D&D† 17 14 5324 10835 -5511 (-15183, 1221) 0.412 0.071 0.340 (0.080, 0.588) [A dominant]
6. 3 m CUA‡ 17 14 5324 10835 -5511 (-15712, 1311) 0.098 0.054 0.044 (0.000, 0.086) [A dominant] 96.5%
* Outcome = proportion surviving; † Outcome = proportion not dead or dependent (defined as mRS<4). ‡ Outcome = QALYs gained; §Differences in 95%CI
around incremental cost in analyses 1, 3 & 5 due to random error from non-parametric bootstrap.
** Threshold of £30,000 only appropriate to £/QALY.
Table 2 Mean Resource use and cost at 14 days and 3 months
14 days 3 months
NN
A P A P A-P A P A P A-P
Mean (SE) Los (days) 112 59 11.49 (0.402) 11.36 (0.577) 0.14 105 57 43.77 (3.38) 49.47 (7.28) -5.7
Median (IQR) LoS (days) 112 59 14 (9, 14) 14 (10,14) 0 105 57 38 (7,84) 34 (10,84) 4.0
Patients still hospitalised n (%) 112 59 76 (67.9) 38 (64.4) 3.45% 105 57 29 (27.6) 16 (28.1) -0.45%
Study drug consumption, vials. Mean (SE) 112 59 4.7 (0.7) 5.7 (1.1) -1.02 112 59 4.7 (0.7) 5.7 (1.1) -1
Study drug consumption, tabs. Mean (SE) 112 59 32.53 (2.3) 45.68 (3.9) -13.15 112 59 32.5 (2.3) 45.7 (3.9) -13.15
Cost of hospitalisation, £, mean (SE) 112 59 2,548 (71) 2,525 (101) 23.78 105 57 8,230 (594) 9,233 (1282) -1,003.60
Cost of study drugs, £, mean (SE) 112 59 4 (1) 0 (0) 4.14 105 59 4 (1) 0 (0) 4
Total cost, £, mean (SE) 112 59 2,553 (71) 2,525 (101) 27.93 (124) 105 57 8,234 (594) 9,233 (1282) -999.50 (1413)
SE = Standard error of the mean, IQR = Inter-quartile range, A = active (labetalol or lisinopril), P = placebo. Note figures may vary
from those reported in Table 1 due to numbers of observations included (see Figure 1).
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analyses 5 and 6 is due to missing data: the figure
quoted in analysis 4 (£1000) is based on substantially
more observations than that in analyses 5 and 6
(£5511), and is therefore subject to less sampling
uncertainty.
At three months, therefore, according to all outcome
measures, active treatment ‘dominates’ placebo (it is on
average less expensive and more effective). We estimate
a 96.5% probability of the incremental cost per QALY
gained being below £30,000 (Table 1 Analysis 6), indeed
irrespective of the threshold, the probability that treat-
ment is cost-effective never falls below 92%.
The above figures are based on complete case analysis.
That is, observations were included in analyses 1-6 only
w h e r ec o m p l e t ec o s ta n do u t c o m ed a t aw e r ea v a i l a b l e
(see Figure 1). We had complete survival data on all 171
patients at three months. However, we were only able to
measure mRS and hence QALYs gained on 32 patients
at 3 months. Therefore the estimate of incremental cost
reported above does not include all observations for
which cost data were available. Looking just at resource
use data (and hence based on n = 105 active + 57 pla-
cebo), we estimate an incremental cost at 3 months of
-£1000 (95% CI: -3450, 1451; Table 2). Similarly, we
estimate incremental QALYs at 3 months at +0.048
(-0.0002, 0.0956; Table 3).
Discussion
To our knowledge, this is the first study examining the
cost-effectiveness of antihypertensive medication imme-
diately post stroke. Other studies have been in the con-
text of primary or secondary prevention of cardio- or
cerebrovascular events in hypertensive patients. These
studies largely favour the use of preventative pharma-
cotherapy [28-30].
On average over three months, we found active treat-
ment within the first 2 weeks of stroke onset to be both
cost saving and outcome improving, leading to active
treatment dominating placebo. However there are
important caveats to bear in mind in interpreting the
results. It should be noted that 95% confidence intervals
around increments were of borderline statistical signifi-
cance (e.g. Table 1, outcomes analyses 4, 5 and 6). It is
highly likely that the analyses with small sample sizes
(e.g. 5 and 6) are subject to selection bias due to poten-
tial correlation between health status and probability of
providing outcomes data at three months (this is likely
‘U-shaped’: sicker individuals are less likely to respond
to request for longer term follow-up data, whilst death
is relatively easy to establish. Indeed, we had mRS and
QALY data on 23 (11, 12) of 31 patients by virtue of
knowledge of date of death).
This was a trial for which data collection proved to be
problematic, particularly in terms of disability status at
three month follow-up. The primary objective of the
study was to assess whether disability and death at two
weeks post stroke was affected by drug induced reduc-
tion of BP [23]. Study recruitment was only 11% of that
for which it was powered, for a variety of reasons
including the inherent difficulty in recruiting patients
within the allowed time frame post ictus,a n dh i g h e r
than anticipated prevalence of pre-treated hypertension
(one of the exclusion criteria).
The economic evaluation component of this study was
added following commencement of the trial via a proto-
col amendment, with research resources permitting only
limited data collection. Therefore the analysis relied
almost exclusively on patient-reported length of stay to
determine the cost of active and placebo treatments (the
cost of the study drugs was trivial), and the perspective
of the analysis was thus restricted to the acute hospital
admitting the stroke patient.
The use of self-reported length of stay is a common
method for data collection in economic evaluations
alongside trials. However, this is subject to recall bias.
Studies of the reliability of self-reported data have
reported mixed results [31,32]. The impact of this on
the study depends on whether the average errors in
length of stay are equal between the arms. Randomisa-
tion should ensure an even distribution of patients more
Table 3 Outcomes at 14 days and 3 months
N
A P A P A-P P-
value
Mean (SE)
utility
Baseline 112 59 0.892 (0.007) 0.899 (0.008) -0.007
14 days 112 59 0.551 (0.022) 0.526 (0.035) 0.026 0.519
3 months 18 14 0.366 (0.100) 0.088 (0.060) 0.278 0.035
Mean (SE) QALYs gained
14 days 112 59 0.028
(0.0005)
0.027
(0.0007)
0.000 0.650
3 months 18 14 0.102
(0.0185)
0.054
(0.0116)
0.048 0.051
Survival n (%)
14 days 112 59 107 (95.54) 53 (89.83) 5.71% 0.148
3 months 112 59 102 (91.07) 47 (79.66) 11.41% 0.034
mRS<4 n (%)
Baseline 112 59 112 (100) 59 (100) 0.00%
14 days 112 59 44 (39.29) 24 (40.68) -1.39% 0.860
3 months 18 14 8 (44.44) 1 (7.14) 37.30% 0.020
*Based on mapped mRS scores
**t-test for continuous variables, c
2 for proportions
A = active, P = placebo. Note figures vary from those reported in Table 1 due
to numbers of observations included (see Figure 1).
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paribus, but it is likely the error will increase with
increasing length of stay. In common with all studies
collecting resource use data in this way, this must be
borne in mind in interpreting the results.
Costing based on length of stay with drug costs added
to this may risk double counting if the unit cost used
f a c t o r si na na l l o w a n c ef o rd r u g s .T h i si sa ni s s u ec o m -
mon to many economic evaluations, and care must be
taken to be sure of what is included in ‘per episode’ unit
costs. In the context of this study, as drug costs were
such a trivial component, the impact on the results
would be negligible.
We did not document readmissions within this study.
However, for this to affect the conclusion of the study,
we estimate that patients in the treatment arm would
on average, need 2.3 to 2.5 additional readmissions per
patient over the three months compared with placebo.
We consider such a large difference to be unlikely,
indeed a priori it may be expected for there to be fewer
readmissions in the active treatment arm. (Please see
Appendix 1 for details).
Figure 1 Complete case analysis sample sizes.
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included within this study by protocol amendment. As
this was after baseline measurements had been taken,
and due to the small numbers of observations, it was
decided to map the mRS scores to utilities and hence
QALYs gained, rather than use the EQ-5D data [23].
The analysis did not take into account uncertainty in
the TTO valuations of the MRS scale [24]. Therefore we
may have underestimated the decision uncertainty,
although this would not affect the point estimate results.
We only had relatively small numbers of observations
for analyses 5 and 6 (reporting incremental cost per
incremental death and disability avoided and QALY;
Table 1). There is therefore danger of the groups being
unbalanced. A comparison of baseline characteristics of
patients included in these analyses shows that they
remain broadly balanced (the tables in additional files 1
and 2 show the baseline characteristics of patients
included in analysis 4 and analyses 5 & 6 respectively),
and results of these analyses are consistent with those of
analysis 4, based on a much larger patient sample.
Given the limitations outlined above, the question that
must be asked is whether any conclusions can be drawn
from such data about a) cost-effectiveness from the
acute setting perspective, and b) the generalisability of
this restricted analytic perspective to wider societal cost-
effectiveness over a longer horizon. Length of stay has
been shown to be the major determinant of acute care
cost [33,34] and therefore our cost estimates could be
plausible indicators of the incremental cost of treating
patients under active or placebo treatment in the acute
setting. The issue of generalisability to wider perspec-
tives is of particular relevance given the high care needs
and associated cost of many stroke survivors (both in
terms of health and social services, and informal carer
time [4,35]).
T h i sc a no n l yb ya n s w e r e de i t h e rt h r o u g hl o n g - t e r m
prospective studies, or through decision analytic model-
l i n g .S u c hap r o s p e c t i v es t u d ym a yb ep r o h i b i t i v e l y
expensive and time consuming to conduct. The model-
ling approach is therefore recommended as a means of
generating an answer within a reasonable time frame,
and the results of this study should be seen as a valuable
input into such an exercise, rather than a definitive esti-
mate of the cost-effectiveness of antihypertensive medi-
cation immediately post stroke. Once such a model has
been developed, value of information analysis may be
used to estimate the likely return from a larger scale
(and longer term) trial [36].
Future trials of treatments in this area wishing to
incorporate an economic aspect to their investigations
should include a) generic quality of life measurement
alongside any disease specific or clinical endpoints and
b) resource use data collection from the outset.
Consideration should be given as to whether at the very
least quality of life and place of residence (i.e. own
home, care home, nursing home) could be relatively
easily measured at, say, six months and one year post
intervention to lengthen the time horizon of any such
study at minimal additional research cost.
Conclusion
Antihypertensive therapy in hypertensive patients imme-
diately post stroke may be effective and cost-effective
compared with placebo from the acute hospital perspec-
tive at three months post ictus. Further research, in par-
ticular decision analytic modelling, is required to
confirm both efficacy and cost-effectiveness and whether
benefits are maintained over a longer time horizon. The
data from this study form a useful input into such a
model.
Appendix 1: The estimated impact of excluding
readmissions
￿ At three months, point estimate results were that
intervention was £5,324 less expensive than control,
and resulted in 0.044 more QALYs, yielding an
ICER of -£121,000 (intervention dominant).
￿ For the ICER to be below £20,000, the cost in the
intervention arm could rise by £6204 (yielding an
incremental cost of +£880 as £880/0.044 = £20,000).
￿ The mean cost of a stroke admission in the study
price year of 2006 was £2642. Therefore the inter-
vention is still cost-effective compared with control
so long as there were less than 6204/2642 = 2.3
more admissions per patient, on average, in the
intervention arm compared with control over the
three month period. (Note this is not total admis-
sions, but 2.3 additional admissions compared with
the control arm.)
￿ for the ICER to be below £30,000, intervention arm
patients must have no more than a average of 2.5
admissions per patient over the three month period.
Additional file 1: Table A2.1. Baseline characteristics of patients
included in analysis 4.
Additional file 2: Table A2.2. Baseline characteristics of patients
included in analyses 5 and 6.
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